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Abstract  
Objectives 
Magnetic Resonance Imaging (MRI) has been increasingly recognized as a critical 
tool for the assessment of patients with rheumatoid arthritis (RA) and is able to 
reliably identify synovitis, bone marrow oedema, bone erosion and joint space 
narrowing/cartilage loss. Understanding the exact relationship between each 
MRI feature and local synovial pathobiology is critical in order to dissect disease 
pathogenesis as well as develop future predictive models.  
Methods 
Therefore a systematic review of the current published literature examining the 
relationship between MRI abnormalities and synovial pathobiology in patients 
with RA was performed.  
Results 
Eighteen studies were identified; most focused on validation of MRI as a tool to 
detect and quantify synovitis with a significant relationship demonstrated. 
Additionally from the limited data available a critical role for synovial pathways 
at least in driving joint damage seems likely. However there was a lack of data 
examining the relationship between synovial pathobiology and bone marrow 
abnormalities and joint space narrowing.  
Conclusions 
Although understanding the inter-relationship of these disease biomarkers 
offers the potential to enhance the predictive validity of modern imaging with 
concomitant synovial pathobiological analysis, further studies integrating MRI 
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with synovial tissue analysis, in well controlled cohorts at distinct disease stages, 
before and after therapeutic intervention are required in order to achieve this.  
 
Introduction 
Magnetic resonance imaging (MRI) is an excellent tool to delineate pathology in 
rheumatoid arthritis (RA) as it is able to define bone, cartilage, fluid and soft 
tissues. This is possible as MRI is able to delineate structures with high water 
content on T2 -weighted (T2w) fat suppressed or short tau inversion recovery 
(STIR) sequences and following injection of gadolinium-DTPA, (Gd-DTPA) 
regions of high vascularity. Thus feasibly MRI can quantify both synovial volume 
and inflammation and act as a surrogate non-invasive marker of histological 
inflammation. Specific MRI features of RA synovial joints have been 
demonstrated to be of particular prognostic value: synovitis, bone marrow 
oedema (BME), bone erosions and cartilage thinning. MRI has the capacity to 
detect bone erosions two years earlier(1) than plain radiographs and sensitivity 
to detect change even in small cohorts(2),  an effect that is of critical relevance 
given the capacity of improved treatment algorithms to halt joint damage(3). 
Consequently MRI is now well recognized as a robust outcome measure in 
clinical trials. 
Historically the pathological events leading to joint damage in RA have been 
suggested to be a sequence of primary synovitis leading to BME, cartilage 
thinning and finally erosions. There is increasing data to challenge this paradigm. 
Firstly although a significant relationship between BME and synovitis (4) and 
between synovitis and the development of bone erosions has been 
demonstrated(5)  debate regarding the exact contribution of synovitis/BME in 
 4 
initiating and/or sustaining bone erosion continues (6) with some evidence 
suggesting that BME per se maybe an independent predictor of erosive 
progression (4,7Ȃ13). Furthermore there is evidence primarily from MRI studies 
to support a biomechanical effect on erosive progression(14). Secondly MRI 
studies have noted BME and erosions as early events with cartilage thinning 
occurring later(15). Thirdly a number of radiographic studies have reported an 
incongruent relationship between cartilage thinning and erosions(15,16). Finally 
recent data have demonstrated an association between MRI documented BME, 
synovitis, baseline cartilage damage and subsequent cartilage loss(17). These 
observations raise a number of fundamental questions regarding mechanisms of 
joint damage and in particular whether synovial pathobiological pathways 
initiate and/or sustain a local environment that drives BME, erosions and/or 
cartilage thinning.  
It was within this context that a systematic literature review was conducted to 
assess published data investigating the relationship between RA synovial 
pathobiology and MRI BME, synovitis, erosions and cartilage thinning.  
 
Methods 
The study methodology was conducted in line with PRISMA guidelines(18) and 
was registered with PROSPERO (http://www.crd.york.ac.uk/NIHR_PROSPERO, 
registration CRD42016033875).  As this was a systematic review no ethics 
approval was sought in accordance with the policy of Barts Health NHS Trust.  
 
Search Strategy 
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Relevant articles, reviews and abstracts were identified through an initial search 
of EMBASE, MEDLINE and the Cochrane Library for articles published up to 
March 2016. The MEDLINE MeSH keyword search terms (Rheumatoid arthritis, 
rheumatoid and arthritis, RA, rheumatoid, inflammatory arthritis, nuclear 
magnetic resonance imaging, magnetic AND resonance AND imaging, synovitis, 
synovi, pathology, histopathology, immunohistochemistry, pathol, histo, 
immune, joint surgery, arthroscopy, biopsy, joints, surgery) and Boolean 
operators adopted are presented in Table 1. These were modified to 
accommodate each search database.  EMBASE and Cochrane search terms are 
presented as supplementary data (Supplementary Tables 1 and 2 respectively). 
 
Eligibility criteria 
Studies including RA patients undergoing a MRI scan of a peripheral synovial 
joint along with sampling of synovial tissue were eligible. Outcome measures for 
MRI scanning included BME, joint erosion, synovitis and cartilage thickness. 
Outcome measures for synovial tissue included macro/microscopic histological 
assessment and immunohistochemical and gene expression analysis. In order to 
be included within the review studies had to directly compare one MRI RA 
feature with one or more synovial outcome measure. All types of study design 
were included and analysis was restricted to humans.  Non English language 
articles with no translation available and abstracts with no corresponding full 
text article were excluded. 
Two reviewers (F.H. and A.M.) independently reviewed the titles and abstracts 
from potentially relevant articles identified through the search strategy. Both 
reviewers assessed the full texts of all potentially eligible articles.  
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Data extraction 
Data were entered onto a pre-defined data extraction table. For each study the 
following data were recorded regarding study design: type of study, disease 
stage (e.g. early vs. established disease), procedure for synovial sampling, time 
interval between synovial sampling and MRI scan, whether concomitant DMARD 
and/or steroid therapy was controlled for, joint imaged and joint biopsied. The 
following MRI parameters were also recorded: MRI feature scored, acquisition 
strength and method of assessment of MRI features.  Additionally the following 
parameters regarding synovial tissue analysis were recorded: number of 
synovial samples taken, procedure for synovial tissue preparation, macroscopic 
assessment of synovium, histological assessment of H&E stained samples, 
immunohistochemical assessment, synovial gene expression analysis and main 
conclusions. Data extraction was performed by one reviewer (F.H.) and was 
verified by a second (A.M). Any disagreements regarding data extraction were 
resolved following discussion between the reviewers. 
 
Quality assessment  
The quality of each study was independently assessed by two reviewers (FH and 
AM) using an adapted standardized quality scoring tool (Supplementary data 
Table 3) (19,20) to assess the following components: i. study population, ii. MRI 
assessment and scoring, iii. Histological assessment, and iv. Study design and 
analysis and data presentation.    Ǯ ?ǯ  Ǯ ?ǯ     ch 
question according to whether the study fulfilled the criteria or not respectively. 
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A study was considered to be high quality if it exceeded or equaled the mean 
score (% of total) in its class (cross sectional vs RCT vs cohort study). 
 
 
Results 
Search Strategy 
A summary of the results of the search strategy is presented in the PRISMA flow 
chart shown in Figure 1. This indicates that a total of 444 articles were identified. 
Following the exclusion of duplicates (n=117) and review articles (n=103) 224 
articles were screened. Of these 188 were excluded (122 as didn't include 
patients with RA, 54 as didn't include histopathological analysis of synovial 
tissue, 7 as examination of tissue in vitro or in animal models and 5 as no MRI 
scans were included). Of the remaining 36 articles 18 were then excluded: 2 as 
no English translation available, 5 as no synovial histopathobiological 
examination (3 no synovial histology and 2 as synovial explants in vitro only), 1 
as no comparison of MRI and synovial pathobiology (not relevant to task), 4 as 
did not include patients with RA and 6 as abstract only with no full text. 18 
articles were then identified that satisfied the eligibility criteria and were 
therefore included in the review.  
 
Characteristics of included studies 
            A summary of the characteristics of the 18 studies is presented in Table 2 (MRI 
characteristics) and Table 3 (histopathobiological characteristics). A total of 442 
participants were included in the analyses from the 18 studies. 327 of these had 
RA, 19 spondyloarthropathy, 4 psoriatic arthritis, 55 osteoarthritis, 2 healthy 
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controls and 35 other arthritic conditions. 11 studies were cross sectional 
observational studies (21Ȃ31) and one study was a retrospective analysis(32). 
Four studies were prospective open label clinical trials(33Ȃ36), one study was a 
blinded randomized clinical trial (RCT)(37) and one study was a prospective 
observational clinical study(38).   Fifteen studies included patients only with 
established RA (although exact disease duration was not specified in two of these 
studies(31,35)and three studies specifically included patients with disease 
duration of <2 years (26,36,38). 14 studies sampled synovium from the knee 
joint and 4 studies included samples from small joints(26,31,32,35). Variable 
methods for synovial sample retrieval were reported: 7 studies utilizing 
arthroscopy (29,31,33,34,36Ȃ38), 4  arthroplasty (21,27,28,32) and three using 
both (22,23,30). Two studies used blind needle biopsy (24,25) and two mini-
arthroscopy (Table 2)(26,35). Acquisition of images was performed on a 1.5T 
MRI scanner with contrast administration in 13 studies(21Ȃ23,26Ȃ30,32Ȃ
34,36,37) and without in one study(38). Two studies used a 0.5T + contrast 
administration (Table 2) (24,25) and two a 3T+ contrast protocol (31,35) 
although the latter study used a 0.2T scanner in a significant proportion of 
patients (4/10) with claustrophobia.  
 
Quality Assessment of Studies  
A summary of quality scoring of studies is provided in supplementary data 
(Supplementary Table 4). Quality scores were converted to percentages of the 
maximum score within each class of study. The mean (range) quality score was 
56% (25Ȃ75) for cross sectional studies and 68% (46Ȃ93) for cohort studies 
indicating a broad range of scores. The one RCT had a quality score of 71%.  
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Clinical results 
Synovitis 
MRI synovitis can be assessed by static and dynamic protocols. Subsequent to 
the acquisition of T1 weighted images (Figure 2A) static protocols assess the 
volume of enhancing synovitis following the administration of a gadolinium-
based contrast agent (Figure 2B) at a fixed time point. Synovitis volume can then 
be assessed manually or using a semi automated method by outlining the 
synovial tissue. Static images can also be assessed using the widely validated 
semi-quantitative OMERACT-RAMRIS synovitis score(39). Dynamic contrast 
enhanced (DCE)-MRI involves the rapid acquisition of sequential images during 
and after administration of contrast and assesses rate of enhancement of 
synovial tissue. Results can be influenced by factors such as synovial perfusion 
and capillary permeability: thus dynamic versus static protocols maybe able to 
more sensitively reflect local synovial inflammatory activity (40,41). 
 
Does MRI synovitis reflect histopathological inflammation?  
            16 studies were identified that directly examined the relationship between the 
degree of MRI synovitis and local synovial pathobiology(21Ȃ25,27Ȃ33,35Ȃ37). 
Macroscopic synovitis and MRI synovitis was assessed in three studies both 
semi-quantitatively(22) and using dynamic MRI protocols (34,37) with all three 
suggesting a significant correlation between macroscopic and MRI synovitis. Six 
studies (21Ȃ24,28,31) using dynamic MRI and three studies (26,27,32) using 
static MRI protocols also directly examined the relationship between MRI 
determined synovitis and synovial inflammation assessed microscopically 
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following routine H&E staining. 8/9 of these studies (21Ȃ24,26Ȃ28,31)  
concluded that histological inflammation correlated with either semi-
quantitative or DCE MRI synovitis. Although immunohistochemical analysis of 
the synovial cell infiltrate was performed in seven studies(27,29,31,33,35Ȃ37) 
only six directly reported the relationship between histological markers and 
synovitis with a significant relationship between MRI synovitis and: CD4+ T cells 
(37), CD68+ sublining macrophage number(27,29,31)cell proliferation (Ki67) 
(27) and neoangiogenesis (CD31)(27) reported. 3/4 studies also reported a 
significant relationship between MRI synovitis and degree of histological 
vascularity through: semi-quantitative assessment of H and E stained tissues 
(30) expression of the neoangiogenesis marker CD31(27), endothelial cell 
marker QBend30 (25) and vWF expression (36). Conversely Vordenbaumen et al 
(35) reported no significant relationship between either sublining macrophage 
number or vascular endothelial growth factor (VEGF) (an immunhistochemical 
marker of vascularization) and RAMRIS synovitis.  
 
Does MRI synovitis capture modulation of synovial pathobiology following 
effective therapeutic intervention? 
Longitudinal data examining whether MRI is sensitive enough to detect 
modulation of histological synovitis following effective therapeutic intervention 
was evaluated in four studies incorporating serial MRI scans and paired synovial 
biopsies. Firstly an open label placebo controlled study of intra articular anti-
CD4(37) reported a significant correlation between MRI synovitis and 
macroscopic synovitis with a trend towards improvements in both histological 
and MRI synovitis only in patients receiving active treatment. Secondly Buch et al 
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(33) in a prospective open label trial reported on the synovial effect of abatacept 
in a cohort of 13 patients. Although this study did not report directly on the 
relationship between modulation of MRI synovitis and synovial histology it did 
report on the relationship between synovial gene expression and MRI synovitis, 
documenting a significant association between down regulation of the T cell 
cytokine IFNɀsynovitis scores in responders to treatment. 
Thirdly a prospective open label trial of 16 RA patients investigated the effect of 
TNF inhibitor therapy on hypoxia, macroscopic and microscopic synovial 
inflammation and MRI synovitis(34). Patients underwent a baseline needle 
arthroscopic synovial biopsy and DCE MRI of the knee both of which were 
repeated 3 months after starting anti-TNF therapy. This study demonstrated a 
significant inverse relationship between hypoxia and clinical response to anti-
TNF therapy. The investigators also looked directly and found a significant 
relationship between macroscopic synovitis/vascularity and MRI synovitis.  
There were also significant associations demonstrated between falls in CD4+ T 
cells and CD68+ sublining macrophages and MRI synovitis. Finally 
Vordenbaumen et al(35) reported results from six patients who underwent 
sequential MCP joint biopsy and MRI and reported no significant association 
between change in sublining macrophage number and RAMRIS synovitis score 
although given the small sample size the significance of the results is unclear.  
The data identified within this review provides an initial basis for the use of MRI 
as a surrogate measure of histological synovitis. Of particular importance is the 
relatively consistent demonstration of a significant relationship between CD68+ 
sublining macrophage number and MRI synovitis, the only current synovial 
biomarker validated as a measure of disease activity(42). However it is also 
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important to consider a number of limitations when interpreting results from 
these studies(21Ȃ23,25Ȃ30,35,37). Firstly it is now recommended that in order 
to overcome significant synovial pathological heterogeneity 6 synovial samples 
from different sites should be analysed for large joint procedures (43) and 4 for 
small joints (44). Although ten studies reported number of synovial samples 
retrieved per procedure (21Ȃ23,26,28,30,33,35,37,38) only four cohorts 
reported retrieving 6 or more biopsies(30,31,33,35). Furthermore only a 
selected number of studies specified a biopsy site predetermined by the MRI 
image (21Ȃ23,28,30,37) and so were able to directly compare local synovial 
pathology. Synovial pathology is also influenced by disease course as well as 
therapeutic intervention(45Ȃ47) factors that were not routinely controlled for in 
a number of studies (21Ȃ23,28,30,32) as a wide variability in time from MRI 
assessment to synovial sampling was reported. In addition, only two 
studies(21,29) reported that intra articular steroid injections were not permitted 
in this period and only three studies(29,33,37) controlled doses of steroids and 
DMARDs prior to study inclusion. It should also be noted that the majority of 
studies identified harvested synovial tissue from arthroplastic knee joint 
procedures (21Ȃ23,27,28,30,32), which restricts sampling of tissue to end stage 
joints. Indeed there was only limited data evaluating pathobiology at distinct 
disease stages from homogenous cohorts with only one study(29) including 
patients specifically with disease duration of less than 1 year and only two 
studies(26,38) including patients with disease duration of less than two years 
(26,38). Importantly of the 18 studies identified thirteen sampled knee joints, 
with only four (26,31,32,35) examining the relationship in small joints.  
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Bone marrow oedema 
MRI is unique amongst currently available imaging modalities in its ability to 
detect BME (Figure 2C) and although outside the remit of this systematic review 
it is worth noting that BME has been shown to equate to histological osteitis(48). 
Importantly the occurrence of BME has been tightly correlated with the presence 
of synovitis (49), however whether BME is driven and/or maintained by synovial 
pathobiological signals is unknown and very limited data examining this 
relationship was identified. Takase et al(27) report that in a cohort of 15 RA 
patients no significant relationship between histopathological changes of 
inflammation (neoangiogenesis, inflammatory cell infiltrates and lining layer 
thickness) and MRI BME were found. In a further cohort of 7 patients in clinical 
remission(32), no correlation between MRI BME and histological synovitis was 
reported; this is likely to be explained by the small number of patients within the 
study. Finally in a cohort of ten patients Vordenbaumen et al (35) report that 
synovial staining for VEGF significantly correlated with RAMRIS BME scores in 
MCP joints. Certainly more complex synovial analysis in larger cohorts at 
different stages of disease will be required to fully interpret whether synovial 
signals are involved or required in the initiation and/or maintenance of BME.   
 
Bone erosion  
MRI has been increasingly recognized as a more sensitive marker of erosions 
(Figure 2D) than plain radiography(50). The validation of the OMERACT-RAMRIS 
MRI score(39) as a robust and sensitive tool to document presence and/or 
erosive progression in patients with RA suggests that incorporating MRI 
progression data with synovial pathobiology may reveal important signatures of 
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disease. In two cross sectional cohorts Andarajah et al (32) reported in 7 
patients with established RA no clear association between histological synovitis 
and erosions(32) and Vordenbaum (35) et al reported a significant relationship 
between synovial VEGF staining and the RAMRIS erosive score in MCP joints in 
10 patients. Interpretation of the significance of these results is complicated by 
the small numbers, cross sectional approach and lack of validated MRI erosion 
score in the former report. However in a prospective study of 60 patients 
Kirkham et al (38) who aimed to examine whether synovial pathobiology could 
explain joint damage progression, as assessed by progression in the OMERACT-
RAMRIS score(51). Although the authors identified no specific synovial 
histological features, using multivariate analysis of gene expression they 
identified IL-1, TNFȽ, IL-17, and IL-10 as predictive of joint damage progression. 
This study had a number of limitations, namely i) a wide range of disease 
duration in patients recruited to the study, ii) lack of control of concomitant 
disease modifying therapies and iii) joint damage progression in the small joints 
of the hands was related to distant synovial sampling sites in the knee. 
Notwithstanding this the report is highly instructive in identifying synovial 
mediators of joint damage progression and it remains important therefore to 
validate the results in further larger cohorts of therapy naïve early RA patients.   
 
Cartilage loss 
Cartilage loss in RA can be assessed by documenting joint space narrowing on 
plain radiographs as well as MRI (Figure 2E). However no data was identified 
within this systematic review to examine the relationship between cartilage loss 
and synovial pathobiology. .  
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Discussion 
MRI has significant advantages over other imaging techniques for patients with 
RA; it does not expose patients to ionising radiation, it can sensitively detect 
synovitis, erosions and joint space narrowing and is unique in its capacity to 
detect BME. This differentiates MRI from ultrasound which although is a 
sensitive measure of histological synovitis (52) can not detect BME and does not 
have validated outcome measures for cartilage loss or bone erosion. The clinical 
studies identified in this review indicate a significant relationship between 
histological and MRI evident synovitis, which is important to validate MRI as a 
tool to reliably assess synovitis without the need for invasive biopsy. 
Furthermore from the limited data available a critical role for synovial pathways 
at least in driving joint damage(38) seems likely but requires more extensive 
validation. However overall the data provides limited information on the specific 
synovial pathobiological processes driving MRI abnormalities in RA.  
Although the past decade has seen tremendous advances in the care of patients 
with RA considerable challenges remain. These include: i) specificity/sensitivity 
of current diagnostic/classification criteria for RA, ii) prediction of prognosis 
following diagnosis of RA, and iii) limited biomarkers of response/resistance to 
biologic drugs. What is required is a move towards an era of personalised 
medicine for patients with RA, with targeted treatment pathways from diagnosis, 
but this is only possible if critical pathways mediating both disease pathogenesis 
and clinical response to therapy are further elucidated. What this review 
highlights is the need to validate the relationship between synovial pathobiology 
and MRI abnormalities at the single joint level both in well defined early and 
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established RA cohorts and within clinical trial protocols of established and 
novel biologic drugs. This is particularly important as historical limitations such 
as the lack of sensitivity of clinical examination and radiographic assessment to 
detect synovitis and joint damage progression/cartilage loss respectively are 
largely overcome by the advent of a robust validated MRI score capable of 
assessing synovitis and erosion(39) and potentially BME and cartilage loss (53). 
Furthermore the advent of techniques such as ultrasound guided synovial biopsy 
(Figure 3) that provide a technically simple, minimally invasive approach to 
tissue acquisition from small as well as large joints(54), and more recent 
techniques to rapidly and simultaneously examine the expression of multiple 
genes are likely to overcome challenges in sampling tissue from previously 
inaccessible joints and variability in histological assessment of synovial tissue.  
Overall the data identified within this systematic review validates MRI as a tool 
to assess synovitis but very limited data directly examining the link between 
synovial pathobiology and joint damage/cartilage loss and BME was identified. . 
Future research should focus on clinical trial protocols integrating synovial 
sampling with MRI imaging at different stages of disease in order to dissect 
critical synovial pathways mediating RA pathogenesis. Although understanding 
the inter-relationship of these disease biomarkers offers the potential to enhance 
the predictive validity of modern imaging with concomitant synovial 
pathobiological analysis further studies, integrating MRI with synovial tissue 
analysis, in well-controlled cohorts before and after therapeutic intervention are 
required in order to achieve this.  
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Figure Legends 
 
Figure 1: PRISMA flow chart presenting the results of the search strategy 
 
Figure 2: Assessment of RA joint abnormalities by magnetic resonance 
imaging.   
Coronal T1 weighted (A)  image of wrist joint demonstrating extensive synovial 
thickening which enhances following administration of gadolinium (B). C. T2 fat 
suppressed coronal image demonstrating bone marrow oedema within the head 
of the proximal and base of the middle phalanx.. D. Axial T1 weighted image 
demonstrating erosions of bone cortex within 2nd and 3rd metacarpal heads E. 
Coronal T1 weighted  image of metacarpal phalangeal (MCP) joints 
demonstrating significant joint space narrowing within second MCP joint 
 
Figure 3. Minimally invasive technique of ultrasound guided synovial 
biopsy of wrist joint.  
Inset depicts corresponding gray scale ultrasound image of biopsy needle 
inserted into wrist joint under extensor tendon complex 
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Table 1. The MEDLINE MeSH keyword search terms and Boolean operators 
1946-to present 
 
Table 2. Summary of studies directly correlating MRI features with synovial 
pathobiology: MRI characteristics  
(DCE: dynamic contrast enhanced, SPP: suprapatellar pouch, Gd: gadolinium, RCT: 
randomized controlled trial, SQ: semi-quantitative, DMARD: disease modifying 
anti-rheumatic drug, ROI:region of interest, NA: not available, *exact timing not 
specified) 
 
Table 3. Summary of studies directly correlating MRI features with synovial 
pathobiology: Histobiological characteristics 
 (DCE: dynamic contrast enhanced, SQ: semi-quantitative, PMN: 
polymorphonuclear, DIA: digital image analysis, IHC: immunohistochemical, MRE: 
maximum rate of enhancement, VAS: visual analogue score, LL: lining layer, SL: 
sublining layer, qRT-PCR: quantitative reverse transcriptase PCR)
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